Group 1 - The core point of the article is that Sihuan Pharmaceutical (00460) has seen its stock price increase by over 9%, currently trading at 1.54 HKD with a transaction volume of 113 million HKD, following the acceptance of a listing application for semaglutide injection by the National Medical Products Administration (NMPA) [1] - The semaglutide injection is intended for improving blood sugar control in adult patients with type 2 diabetes, marking a significant advancement in the drug development process for Sihuan Pharmaceutical [1] - The drug has also completed Phase III clinical enrollment for its weight loss indication and is currently in the follow-up stage, indicating ongoing progress in its clinical development [1] Group 2 - Diabetes treatment is a key focus area for Huisheng Biopharmaceutical, a non-wholly owned subsidiary of Sihuan Pharmaceutical, and the acceptance of the listing application enhances the company's competitive edge in this therapeutic area [1]
港股异动 | 四环医药(00460)涨超9% 惠升生物旗下司美格鲁肽注射液上市申请获国家药监局受理